Use of self-expandable metallic stents for endoscopic biliary decompression decreases stent complications in pancreatic cancer patients receiving chemotherapy.
Chemotherapy
Cholangitis
Endoscopic biliary decompression
Pancreatic cancer
SEMS
Journal
Surgical endoscopy
ISSN: 1432-2218
Titre abrégé: Surg Endosc
Pays: Germany
ID NLM: 8806653
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
01
10
2020
accepted:
13
01
2021
pubmed:
4
2
2021
medline:
3
3
2022
entrez:
3
2
2021
Statut:
ppublish
Résumé
Both plastic stents and self-expandable metallic stents (SEMSes) are used for endoscopic biliary decompression (BD) among patients with pancreatic cancer (PAC). Cholangitis or stent occlusion often interrupts or ends chemotherapy. We investigated cholangitis, stent occlusion, and chemotherapy interruption rates for SEMSes and plastic stents among patients receiving chemotherapy for PAC. We retrospectively analyzed data for 293 PAC patients who received a biliary stent at Helsinki University Hospital during 2000-2017. Patients received chemotherapy as palliative treatment (PT: n = 187) or neoadjuvant treatment (NAT: n = 106). Among participants, 229 had a plastic stent (PT: n = 138, NAT: n = 91) and 64 had a SEMS (PT: n = 49, NAT: n = 15). Overall, 15.6% (n = 10) of patients with SEMSes (PT: 20.4%, n = 10, NAT: 0%) and 53.0% (n = 121) of patients with plastic stents (PT: 69.3%, n = 95, NAT: 28.5%, n = 26) experienced one or more stent complications (p < 0.001). Cholangitis developed in 6.3% (n = 8) of PT patients with SEMSes. No patients with SEMSes receiving NAT (n = 15) experienced cholangitis. However, 31.9% (PT: 42.8%, n = 59, p = 0.001; NAT: 15.4%, n = 14, p = 0.211) of patients with plastic stents developed cholangitis. Among all patients receiving NAT or PT, cholangitis interrupted chemotherapy 6 times (9.4%) in SEMS patients and 61 times (26.6%) in plastic stent patients (p = 0.004). Stent occlusion without cholangitis interrupted NAT or PT 2 times (2.1%) in SEMS patients and 31 times (13.5%) in plastic stent patients (p = 0.023). SEMS is recommended for BD among patients with PAC receiving chemotherapy. Among both PT and NAT patients, patients with SEMS experience a lower stent failure rate, lower rate of cholangitis, and fewer chemotherapy interruptions than patients with plastic stents.
Sections du résumé
BACKGROUND
Both plastic stents and self-expandable metallic stents (SEMSes) are used for endoscopic biliary decompression (BD) among patients with pancreatic cancer (PAC). Cholangitis or stent occlusion often interrupts or ends chemotherapy. We investigated cholangitis, stent occlusion, and chemotherapy interruption rates for SEMSes and plastic stents among patients receiving chemotherapy for PAC.
MATERIALS AND METHODS
We retrospectively analyzed data for 293 PAC patients who received a biliary stent at Helsinki University Hospital during 2000-2017. Patients received chemotherapy as palliative treatment (PT: n = 187) or neoadjuvant treatment (NAT: n = 106). Among participants, 229 had a plastic stent (PT: n = 138, NAT: n = 91) and 64 had a SEMS (PT: n = 49, NAT: n = 15).
RESULTS
Overall, 15.6% (n = 10) of patients with SEMSes (PT: 20.4%, n = 10, NAT: 0%) and 53.0% (n = 121) of patients with plastic stents (PT: 69.3%, n = 95, NAT: 28.5%, n = 26) experienced one or more stent complications (p < 0.001). Cholangitis developed in 6.3% (n = 8) of PT patients with SEMSes. No patients with SEMSes receiving NAT (n = 15) experienced cholangitis. However, 31.9% (PT: 42.8%, n = 59, p = 0.001; NAT: 15.4%, n = 14, p = 0.211) of patients with plastic stents developed cholangitis. Among all patients receiving NAT or PT, cholangitis interrupted chemotherapy 6 times (9.4%) in SEMS patients and 61 times (26.6%) in plastic stent patients (p = 0.004). Stent occlusion without cholangitis interrupted NAT or PT 2 times (2.1%) in SEMS patients and 31 times (13.5%) in plastic stent patients (p = 0.023).
CONCLUSIONS
SEMS is recommended for BD among patients with PAC receiving chemotherapy. Among both PT and NAT patients, patients with SEMS experience a lower stent failure rate, lower rate of cholangitis, and fewer chemotherapy interruptions than patients with plastic stents.
Identifiants
pubmed: 33534073
doi: 10.1007/s00464-021-08327-y
pii: 10.1007/s00464-021-08327-y
pmc: PMC8741707
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
614-620Informations de copyright
© 2021. The Author(s).
Références
Endosc Int Open. 2018 Jun;6(6):E714-E721
pubmed: 29868636
Sci Rep. 2020 Aug 4;10(1):13080
pubmed: 32753642
Gastrointest Endosc. 1991 May-Jun;37(3):383-93
pubmed: 2070995
J Clin Gastroenterol. 2010 Oct;44(9):646-52
pubmed: 20142756
Surgery. 2017 Apr;161(4):939-950
pubmed: 28043693
World J Gastroenterol. 2016 Jul 14;22(26):6065-75
pubmed: 27468198
World J Gastroenterol. 2018 Nov 21;24(43):4846-4861
pubmed: 30487695
Endoscopy. 2018 Sep;50(9):910-930
pubmed: 30086596
Surg Endosc. 2011 Jul;25(7):2364-7
pubmed: 21373939
N Engl J Med. 2010 Jan 14;362(2):129-37
pubmed: 20071702
Gastrointest Endosc. 2012 Jul;76(1):67-75
pubmed: 22483859
Scand J Surg. 2015 Jun;104(2):79-85
pubmed: 25028410
Gastrointest Endosc. 2019 Oct;90(4):602-612.e4
pubmed: 31276674
Gut. 2016 Dec;65(12):1981-1987
pubmed: 26306760
Gastrointest Endosc. 2015 Feb;81(2):360-6
pubmed: 25442083
HPB (Oxford). 2019 Jun;21(6):662-668
pubmed: 30522947